Dr simon plummer

Simon Plummer: Managing Director of MicroMatrices a company with specialist expertise in the molecular phenotyping of tissues and organoid models.
MicroMatrices Associates offer:
• SpheroMatrices, a proprietary spheroid tissue microarray technology, for de-risking drug safety/efficacy studies addressing translatability issues in preclinical drug testing via new analytical techniques for profiling 3D organotypic models: spheroids, organoids, PDX spheroids.
• Specialist services for risk assessment ( Investigative Toxicology) elucidating toxicological/therapeutic mechanisms through the application of integrated genomic/epigenomic/proteomic profiling (mRNA, miRNA, ChIP on chip, LC MS/MS) and pathways analysis.
Toxicological/pharmacological mechanisms are very often cell type specific. MicroMatrices specialises in high resolution cell type-specific analyses to characterise efficacy/toxicity responses in different cell types in the tissue ; please see our website (www.micromatrices.com) for details/case studies.
This approach can facilitate the design of better in vitro models for assessing the relevance/ translatability of mechanisms identified in animal models to man.